Value-based pricing: Who should set drug prices in the UK?
This article was originally published in Scrip
Executive Summary
While the UK's NHS and pharma sector ponder who may end up negotiating drug prices in light of a new white paper, health economists Stuart Carroll, Neil Hawkins and David A Scott contemplate four options which keep NICE very much in the picture